Free Trial
NASDAQ:CABA

Cabaletta Bio Q4 2024 Earnings Report

Cabaletta Bio logo
$1.34 +0.09 (+7.20%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.37 +0.03 (+2.16%)
As of 05/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cabaletta Bio EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.65
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Cabaletta Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cabaletta Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Cabaletta Bio's Q1 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cabaletta Bio Earnings Headlines

Cabaletta Bio price target lowered to $13 from $26 at Stifel
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
Cabaletta Bio price target lowered to $3 from $6 at Wells Fargo
Cabaletta Bio price target lowered to $7 from $10 at UBS
See More Cabaletta Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cabaletta Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cabaletta Bio and other key companies, straight to your email.

About Cabaletta Bio

Cabaletta Bio (NASDAQ:CABA), a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

View Cabaletta Bio Profile

More Earnings Resources from MarketBeat